Products
- Anti-Obesity Compound Library
- GPCR/G Protein-Targeted Compounds
- Immunology/Inflammation-Targeted Compounds
- JAK/STAT-Targeted Compounds
- MAPK-Targeted Compounds
- Membrane Transporter/Ion Channel-Targeted Compounds
- Metabolism-Targeted Compounds
- NF-κB-Targeted Compounds
- Microbiology/Virology-Targeted Compounds
- Neuronal Signaling-Targeted Compounds
- PI3K/Akt/mTOR-Targeted Compounds
- Oxidation-reduction-Targeted Compounds
- Proteases/Proteasome-Targeted Compounds
- Stem Cells/Wnt-Targeted Compounds
- Tyrosine Kinase/Adaptors-Targeted Compounds
- Ubiquitin-Targeted Compounds
Online Inquiry
FH535
Cat. No.:
0225LY-0915
Appearance:
Solid
Purity:
≥99%
Identity:
Confirmed by NMR, and LC-MS.
Size:
Add to basket
Product Overview
Description:
FH535 is a dual inhibitor of PPAR and Wnt/β-catenin signaling that possesses anti-tumor properties.
Synonym:
108409-83-2; 2,5-dichloro-N-(2-methyl-4-nitrophenyl)benzenesulfonamide; beta-Catenin/Tcf Inhibitor, N-(2-Methyl-4-nitrophenyl)-2,5-dichlorobenzenesulfonamide; FH 535; FH-535; 2,5-dichloro-N-(2-methyl-4-nitrophenyl)-benzenesulfonamide; N-[2-methyl-4-nitrophenyl]-2,5-dichlorobenzenesulfonamide
CAS No.:
108409-83-2
Compound CID:
3463933
Formula:
C13H10Cl2N2O4S
Formula Weight:
361.2
Specification
Relative Density:
1.566 g/cm3
Stability:
3 years in powder form.
Storage:
Storage at -20°C.
Applications:
FH535 can be used in oncology research to study the dual inhibition of Wnt/beta-catenin and PPAR signaling pathways.
Library Information
Target:
Wnt/beta-catenin; PPAR
Receptor:
PPARγ; PPARδ; Wnt/β-Catenin
Pathways:
Stem cell regulation; Metabolism; Cytoskeletal signaling; DNA damage/DNA repair
Plate Number:
AOCL-12
Plate Location:
g6
Empty Location:
a1-h1; a12-h12
Container:
96-well plate
Formulation:
10mM DMSO
DMSO Max Solubility:
65 mg/mL; 179.96 mM
ALogP:
4.027
HBA_Count:
2
HBD_Count:
1
Rotatable Bond:
4
